MarketInOut Stock Screener Log In | Sign Up

Faron Pharmaceuticals Oy

HEL • Healthcare • Biotechnology • Quote as of 10/30/2026
Faron Pharmaceuticals Oy stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeHEL
Market Capitalization76.28 mln
Float138 mln
Earnings Date03/19/2027

Piotroski F-Score

2 / 9
Weak

Relative Strength

31 / 100
Underperforming

Debt / Equity

1.55
High leverage

ROA

-71.34
Deeply negative

Business Description

Faron Pharmaceuticals, founded in 2003 and based in Turku, Finland, is a clinical-stage biotech company focused on developing new treatments for cancer and serious immune-related conditions. Its most advanced drug, bexmarilimab, works by reprogramming certain immune cells within tumors to help the body fight cancer more effectively, and is being tested across a range of blood cancers and solid tumors. The company is also exploring how key immune receptors influence organ damage and bone marrow recovery.

Key Fundamentals

EPS-0.11
RPS0.01
ROIC-152
ROA-71.34
EBITDA, mln-13.59
EV / EBITDA-2.69
EV / EBIT-2.62

Quote Details

Last 0.37
Change -0.013 (-3.39%)
Open 0.3825
Volume 391,528
Turnover 144,865
Average Volume 610,195

Financial Ratios

Current Ratio2.40
Price / Book6.43
Price / Tangible Book7.50
Debt / Equity1.55

Financial Strength

Piotroski F-Score 2 / 9

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.73% 40 / 100   
1 Month -10.41% 24 / 100   
2 Months -23.79% 7 / 100   
6 Months -25.7% 12 / 100   
1 Year -82.87% 1 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog